Pancreatic Cell News 7.46 November 22, 2016 | |
| |
TOP STORYResearchers conducted genome-wide CRISPR–Cas9 screens in RNF43-mutant pancreatic ductal adenocarcinoma cells, which rely on Wnt signaling for proliferation. [Nat Med] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISScientists report single cell transcriptomes for 638 cells from non-diabetic and type 2 diabetes human islet samples. [Genome Res] Full Article Pancreatic Beta Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes Beta-cell failure in type 2 diabetes (T2D) was recently proposed to involve dedifferentiation of beta-cells and ectopic expression of other islet hormones, including somatostatin and glucagon. Investigators showed that gastrin, a stomach hormone typically expressed in the pancreas only during embryogenesis, is expressed in islets of diabetic rodents and humans with T2D. [Diabetes] Abstract Scoparone Protects against Pancreatic Fibrosis via TGF-β/Smad Signaling in Rats Researchers investigated the influence of scoparone on pancreatic fibrosis in vitro and in vivo. [Cell Physiol Biochem] Full Article Pdcd2l Promotes Palmitate-Induced Pancreatic Beta-Cell Apoptosis as a FoxO1 Target Gene Investigators determined the regulation of FoxO1 on programmed cell death 2-like (Pdcd2l) expression and explored the role of Pdcd2l on palmitate-induced β cell apoptosis. [PLoS One] Full Article Autophagy Protects against Cholesterol-Induced Apoptosis in Pancreatic β-Cells Autophagy is believed to play an important role in maintaining homeostasis in pancreatic β-cells during insulin resistance. Scientists investigated the role of autophagy in β-cell damage induced by cholesterol and its possible activation mechanism. [Biochem Biophys Res Commun] Abstract PANCREATIC CANCERScientists demonstrated that the BE-43547 subclass of the amidopentadienoate-containing cyclolipodepsipeptides (APD-CLD) natural products possesses highly hypoxia-selective growth-inhibitory activity against pancreatic cancer cells. [Nat Chem] Abstract Quantitative Secretomic Analysis of Pancreatic Cancer Cells in Serum-Containing Conditioned Medium Recently, the metabolic labeling, protein equalization, protein fractionation and filter-aided sample preparation strategy has been successfully used to avoid the disturbance of serum on secretome analysis. This efficient method was applied for comparative secretome analysis of two hamster pancreatic cancer cells with differentially metastatic potentials, enabling the observation of 161 differentially expressed proteins, including 106 proteins that had been previously reported and detected in plasma. [Sci Rep] Full Article Previous research showed that the HDAC inhibitor chidamide is a promising anti-cancer agent in pancreatic cancer cell lines. Scientists elucidated a probable underlying anti-cancer mechanism of chidamide involving the degradation of Mcl-1. [PLoS One] Full Article | |
| |
REVIEWSImmunopathogenesis of Pancreatitis The authors focus pancreatitis pathogenesis and try to establish the thesis that innate immune responses are an integral part of the pathogenesis of pancreatitis. [Mucosal Immunol] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSBoston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer Boston Biomedical announced that its lead investigational compound, napabucasin, has received Orphan Drug Designation from the U.S. Food and Drug Administration in the treatment of pancreatic cancer. [Boston Biomedical] Press Release AzurRx BioPharma Inc. announced that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency caused by chronic pancreatitis. [AzurRx BioPharma Inc.] Press Release Celyad Announces the Approval to Initiate Its NKR-2 CAR-T Clinical Trial in Belgium Celyad announces the approval in Belgium to initiate the THINK clinical trial. THINK is the second clinical trial of its NKR-2 product candidate, a CAR-T cell therapy using NKG2D ligands as a target, to evaluate safety and efficacy in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). [Celyad] Press Release Intarcia Therapeutics, Inc. announced it has submitted its New Drug Application to the U.S. Food and Drug Administration (FDA) for ITCA 650 for the treatment of type 2 diabetes. [Intarcia Therapeutics, Inc.] Press Release Ruga Corporation announced the company’s name change to Aravive Biologics, Inc., and the relocation of its business operations to Houston, Texas. The move follows the company’s award of a $20 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), which is supporting the development of a novel drug candidate, Aravive-S6, as a potential treatment for acute myelogenous leukemia and solid tumors including ovarian, pancreatic, and breast cancers. [Aravive Biologics, Inc.] Press Release | |
| |
POLICY NEWSImmigrant and Minority Scientists Shaken by Trump Win Scientists are reconsidering whether to work or study in the United States. Worries include job prospects, discrimination — and safety. [Nature News] Editorial Peer-Review ‘Heroes’ Do Lion’s Share of the Work In 2015, the number of scientists in the life sciences far exceeded the demand on them for peer review, according to Michail Kovanis, a computational physicist at the French National Institute of Health and Medical Research in Paris, and his colleagues. Yet their study also suggests – based on data obtained from a rapidly-growing website of peer-review activity – that 20% of the scientists undertook between 69% and 94% of reviews last year, lending credence to some researchers’ complaints that they are overburdened. [Nature News] Editorial Cautious Welcome for UK’s Vague £2 Billion Research Pledge UK scientists have welcomed a surprise government promise to invest an extra £2 billion (US$2.5 billion) per year into research and development by 2020 – although details of the pledge will not be made clear for at least another two days. [Nature News] Editorial Conservatives, Liberals Team Up against Animal Research “Painful, bizarre, and wasteful experiments.” Buying dogs “just to cut them apart … and kill them.” These statements might sound like the rhetoric used by extreme animal rights groups, but they come from White Coat Waste—a new, unlikely coalition of fiscal conservatives and liberal activists that aims to end federal funding for research involving dogs and other animals by targeting people’s pocketbooks in addition to their heartstrings. [ScienceInsider] Editorial
| |
EVENTSNEW The American Association for Cancer Research (AACR) Annual Meeting 2017 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Professor (Dartmouth College / Geisel School of Medicine) NEW Postdoctoral Research Associate – Structural Biology (Arizona State University) NEW Faculty Position – Cancer Immunology (University of New Mexico) Assistant Professor – Cancer Cell Biology (North Dakota State University) Postdoctoral Position – Diabetes Research (Institute of Physiology of the Czech Academy of Sciences) Research Fellow – Genome Regulation and Diabetes (Imperial College London) Postdoctoral Scholar – Diabetes Research (University of Oklahoma Health Science Center) Postdoctoral Researcher – Type II Diabetes and Islet Biology (Lund University) Postdoctoral Fellow – Cancer and Immunometabolism (The University of Michigan) Postdoctoral Researcher – Pancreatic Cancer (Van Andel Research Institute) Postdoctoral Position – Immunology of Diabetes (INSERM) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Postdoctoral Research Fellow – Pancreas Cancer (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.46 | Nov 22 2016